Author

@Asktraders1 Asktraders1

grade Ccorporatex.com/Asktraders1 ↗

High-volume UK/US pre-market news and analyst-roundup aggregator, no original analysis

Publishes a steady stream of pre-market mover lists, sell-si

trader score
·
hit rate
·
mean α
·
signals 14d
90

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.

Their picks, scored

Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved -0.7% since posting (mean over 18 mentions with price data).

Recent signals15receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-08-28·@Asktraders1·Forgent will increase its Peak Hill stake to 99% before an 8,700-meter drilling campaign.·
2026-08-28·@Asktraders1·Reports Forgent's share count reached 44.4 billion after a £0.8M placing, further diluting holders.·
2026-08-28FORG@Asktraders1-0.60Forgent hit a fresh low after interim results and a dilutive £0.8M placing.·
2026-08-28·@Asktraders1·Reports net liabilities fell from €7.03M to €3.13M after debt conversion and an equity placing.·
2026-08-28GILD@Asktraders1+0.25Gilead now has a new single-tablet HIV treatment based on Biktarvy and lenacapavir.
2026-08-28GILD@Asktraders1+0.50Gilead won FDA approval for the once-daily Bixlenvo HIV regimen.
2026-08-28GILD@Asktraders1+0.35Reports Gilead's Q2 HIV sales reached $5.7B, up 12%, alongside Bixlenvo's US approval.
2026-08-28GILD@Asktraders1+0.35Phase 3 data showed efficacy comparable to Biktarvy; Q2 Biktarvy revenue was $3.8B, up 7%.
2026-08-28GDWN.L@Asktraders1+0.25Goodwin plans to return some sale proceeds to shareholders and target zero net debt.·
2026-08-28·@Asktraders1·Goodwin confirmed Rothschild is running a sale process for a major division generating £211M revenue.·
2026-08-28·@Asktraders1·Reports trading profit rose 118%, revenue 27% and the dividend 18%, but the ticker is only in thread context.·
2026-08-28GDWN@Asktraders1+0.55Goodwin shares jumped over 10% after record annual results and confirmation of a divisional sale.·
2026-08-27ZM@Asktraders1+0.20Reports Zoom rebounding 3.03% to $96.67.-1.8%
2026-08-27ZM@Asktraders1-0.30Reports below-consensus Q3 EPS guidance despite higher full-year guidance.-1.8%
2026-08-27ZM@Asktraders1-0.50Reports Zoom falling 7% after Q3 profit guidance missed consensus despite a Q2 beat.-1.8%

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.